Titration of AAV-2 particles via a novel capsid ELISA: Packaging of genomes can limit production of recombinant AAV-2

Gene Therapy

Volumn 6, Issue 7, 1999, Pages 1322-1330

  Grimm, D ^a   Kern, A ^a   Pawlita, M ^a   Ferrari, F K ^b   Samulski, R J ^c   Kleinschmidt, J A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b PRINCETON UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

AAV 2; AAV 2 ELISA; AAV 2 titration; Recombinant AAV 2

Indexed keywords

MONOCLONAL ANTIBODY;

ADENO ASSOCIATED VIRUS; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; PRIORITY JOURNAL; VIRUS CAPSID; VIRUS GENOME; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANTIBODIES, MONOCLONAL; CAPSID; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2; MIRIDAE;

EID: 0032773889     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300946     Document Type: Article

References (41)

1. Berns KI, Bohensky RA. Adeno-associated viruses: an update. Adv Vir Res 1987; 32: 243-305.
2. Alexander IE, Russell DW, Spence AM, Miller AD. Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. Hum Gene Ther 1996; 7: 841-850.
3. Kaplitt MG, Makimura H. Defective viral vectors as agents for gene transfer in the nervous system. J Neurosci Meth 1997; 71: 125-132.
4. McCown TJ et al. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996; 713: 99-107.
5. Podsakoff G, Wong KK, Chatterjee S. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 1994; 68: 5656-5666.
6. Russell DW, Miller AW, Alexander IE. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 1994; 91: 8915-8919.
7. Kotin RM et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87: 2211-2215.
8. Samulski RJ et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991; 10: 3941-3950.
9. Balague C, Kalla M, Zhang WW. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 1997; 71: 3299-3306.
10. Kessler PD et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996; 93: 14082-14087.
11. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-8108.
12. Flotte TR et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993; 90: 10613-10617.
13. Kaplitt MG et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
14. Klein RL et al. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol 1998; 150: 183-194.
15. Peel AL et al. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Therapy 1997; 4: 16-24.
16. Flannery JG et al. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 6916-6921.
17. Snyder RO et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
18. Snyder RO, Xiao X, Samulski RJ. Production of recombinant adeno-associated viral vectors. In: Dracopoli N et al (eds). Current Protocols in Human Genetics. John Wiley: New York, 1996, pp 12.1.1-12.1.24.
19. Atkinson EM, Debelak DJ, Hart LA, Reynolds TC. A high-throughput hybridization method for titer determination of viruses and gene therapy vectors. Nucleic Acids Res 1998; 26: 2821-2823.
20. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998; 9: 2745-2760.
21. Flotte TR et al. Gene expression from adeno-associated virus vectors in airway epithelial cells. Am J Respir Cell Mol Biol 1992; 7: 349-356.
22. Salvetti A et al. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998; 9: 695-706.
23. Clark KR, Voulgaropoulou F, Johnson PR. A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Therapy 1996; 3: 1124-1132.
24. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.
25. Fisher KJ et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-532.
26. Wistuba A et al. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol 1997; 71: 1341-1352.
27. Steinbach S, Wistuba A, Bock T, Kleinschmidt JA. Assembly of adeno-associated virus type 2 capsids in vitro. J Gen Virol 1997; 78: 1453-1462.
28. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
29. Chen CA, Okayama H. Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotech 1988; 6: 632-638.
30. Samulski RJ, Berns KI, Tan M, Muzyczka N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 1982; 79: 2077-2081.
31. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63: 3822-3828.
32. Heilbronn R, Bürkle A, Stephan S, zur Hausen H. The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification. J Virol 1990; 64: 3012-3018.
33. Zolotukhin S et al. A 'humanized' green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 1996; 70: 4646-4654.
34. de Wet JR et al. Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 1987; 7: 725-737.
35. MacGregor GR, Caskey CT. Construction of plasmids that express E. coli beta-galactosidase in mammalian cells. Nucleic Acids Res 1989; 17: 2365.
36. Rittner K, Stoppler H, Pawlita M, Sczakiel G. Versatile eucaryotic vectors for strong and constitutive transient and stable gene expression. Meth Mol Cell Biol 1991; 2: 176-181.
37. Fisher KJ et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med 1997; 3: 306-312.
38. Myers MW, Carter BJ. Assembly of adeno-associated virus. Virol 1980; 102: 71-82.
39. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
40. Vincent KA, Piraino ST, Wadsworth SC. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J Virol 1997; 71: 1897-1905.
41. Weger S, Wistuba A, Grimm D, Kleinschmidt JA. Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and Rep proteins. J Virol 1997; 71: 8437-8447.